Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

pre-eclampsia/tyrosine

L'enllaç es desa al porta-retalls
Pàgina 1 des de 1022 resultats
OBJECTIVE To investigate the possible impact of thrombin on soluble Fms-like tyrosine kinase 1 (sFlt-1) expression in trophoblasts. METHODS Experimental. METHODS University hospital laboratory. METHODS A trophoblast cell line (HRT-8/SVneo) was treated with thrombin, protease-activated receptor 1

Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The primary placental defect in preeclampsia is shallow trophoblast invasion of the decidua leading to incomplete vascular transformation and inadequate uteroplacental perfusion. Soluble fms-like tyrosine kinase-1 (sFlt-1) seems to interfere with these events by inhibiting local angiogenesis and/or

Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE The purpose of this study was to determine if maternal serum concentrations of placenta growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 receptor (s-Flt1) are more abnormal in patients with severe preeclampsia compared with mild preeclampsia. METHODS Serum samples were collected
The primary driving force in preeclampsia (PE) appears to be excessive secretion of fms-like tyrosine kinase-1 (sFlt-1), a truncated decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) that induces systemic endotheliopathy by depriving endothelial cells of

Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND Increased maternal plasma levels of proinflammatory cytokines as well as the anti-angiogenic agents soluble fms-like tyrosine kinase 1 (sFlt-1) and endoglin (sEng) are associated with promoting vascular dysfunction leading to the maternal syndrome of preeclampsia. OBJECTIVE Nulliparous
Invasive deficiency of the trophoblast and poor remodeling of the uterine spiral arteries were probably the primary pathogenesis causes of preeclampsia (PE). The expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) during embryogenesis had been previously confirmed and
OBJECTIVE We measured maternal serum soluble fms-like tyrosine kinase 1 concentrations across pregnancy and immediately postpartum in women who developed preeclampsia and normal pregnant women. METHODS This was a nested case control study of 113 normal pregnant women and 55 women with

Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To explore angiogenic factor differences in preeclamptic patients according to the absence or presence of underlying vascular disease. METHODS We prospectively compared serum soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin, and placental growth factor (PlGF) from 41

Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The pathophysiology of preeclampsia remains largely unknown. A number of circulating placenta-produced factors have been implicated in causing the endothelial dysfunction and the clinical phenotype characteristic of preeclampsia. OBJECTIVE Determination of serum levels of placental soluble fms-like
OBJECTIVE Performance evaluation of the novel BRAHMS KRYPTOR soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) assays. METHODS Intra- and inter-assay imprecision, functional sensitivity, linearity in dilution, method comparison, and diagnostic capacity were
T helper (Th)1 cytokine-predominating status and compromised placental vasculature is thought to be central to the pathogenesis of preeclampsia. However, it remains to be clarified how these two phenomena relate to each other. We have reported that lymphokine-activated killer (LAK) cells induced
OBJECTIVE The aim of this investigation was to assess soluble endoglin (sEng) and soluble fms-like tyrosine kinase-1 (sFlt1) as first-trimester serum markers to predict preeclampsia. METHODS First-trimester sera were obtained from 46 women with subsequent late-onset preeclampsia and from 92

Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE To estimate whether alterations in plasma levels of the proangiogenic proteins placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A), and the antiangiogenic protein soluble fms-like tyrosine kinase-1 (sFlt1) were more pronounced in early-onset than in late-onset
OBJECTIVE To investigate the maternal plasma concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and free vascular endothelial growth factor (free-VEGF) at 11 to 13 weeks of gestation in patients destined to develop preeclampsia (PE) and to examine whether any possible differences in
Background: We retrospectively investigated soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratios and screen-positive rates according to cutoff values for preeclampsia risk assessment based on the number of
Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge